Burzynski Research Institute Inc., a company dedicated to the research and development of Antineoplaston drugs for cancer treatment, has released its Form 10-Q report for the first quarter of fiscal year 2024. The report highlights the company's financial performance and operational activities amidst ongoing clinical trials and regulatory challenges.
Financial Highlights
- Net Loss: The company reported a net loss of $371,332 for the three months ended May 31, 2024, compared to a net loss of $287,405 for the same period in 2023. This increase in net loss is primarily due to higher research and development costs and general and administrative expenses.
- Basic and Diluted Loss Per Common Share: The basic and diluted loss per common share remained at $(0.00) for both the three months ended May 31, 2024, and 2023.
- Research and Development Costs: Research and development costs increased by $44,000 or 24% from the previous year, totaling $226,088. The increase is primarily due to higher facility and equipment costs, consulting, and personnel costs.
- General and Administrative Expenses: General and administrative expenses increased by $40,000 or 38% compared to the same period in 2023, amounting to $145,244. This rise is mainly due to higher legal and professional costs related to clinical hold discussions and regulatory reporting requirements.
Business Highlights
- Research and Development Focus: The company is primarily engaged in the research and development of Antineoplaston drugs for cancer treatment. The clinical trials are currently under a full clinical hold by the FDA, impacting the ability to enroll new patients.
- Clinical Trials and Regulatory Status: The company's investigational new drug application (IND) 43742 is under full clinical hold, preventing new patient enrollment. The company is working to address FDA concerns to lift the hold.
- License Agreement Developments: A new License Agreement was entered into with Dr. Burzynski on May 22, 2023, granting exclusive rights in the U.S. and Canada for Antineoplastons, contingent on FDA approval.
- Operational Dependency: The company is economically dependent on funding from Dr. Burzynski's medical practice, which has historically supported research activities. This dependency poses a risk if funding ceases.
- Future Outlook: The company anticipates spending approximately $900,000 in the remaining quarters of the fiscal year ending February 28, 2025, with continued reliance on Dr. Burzynski for funding.
SEC Filing: